close

Fenwick & West Represents Oncothyreon in $22M Shelf Takedown

February 11, 2015

Fenwick & West represented Oncothyreon (NASDAQ: ONTY), biopharmaceutical company focused on the development of therapeutic products for cancer treatment, in its underwritten public offerings of 13,500,000 shares of its Common Stock at a price to the public of $1.50 per share for gross proceeds of approximately $20 million and 1,333 shares of its Series B Convertible Preferred Stock at a price to the public of $1,500 per share for gross proceeds of approximately $2 million. The offerings are being made pursuant to an effective shelf registration statement previously filed with the SEC.  As part of the Common Stock offering, Oncothyreon also expects to grant the underwriters a 30-day option to purchase additional shares of its Common Stock.

Jefferies LLC acted as the sole book-running manager for the offerings.

The Fenwick transaction team included corporate attorneys Alan Smith, Jamie Evans, Effie Toshav, Amanda Rose and Ryan McRobert.